持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/10/08 | 3,445 | 3,505 | 3,430 | 3,460 | ±0 | ±0% | 28,400 |
2024/10/07 | 3,495 | 3,495 | 3,435 | 3,460 | -20 | -0.6% | 24,000 |
2024/10/04 | 3,440 | 3,495 | 3,440 | 3,480 | +40 | +1.2% | 24,700 |
2024/10/03 | 3,430 | 3,455 | 3,415 | 3,440 | +45 | +1.3% | 18,400 |
2024/10/02 | 3,320 | 3,425 | 3,320 | 3,395 | +20 | +0.6% | 26,400 |
2024/10/01 | 3,350 | 3,390 | 3,300 | 3,375 | +20 | +0.6% | 16,500 |
2024/09/30 | 3,310 | 3,400 | 3,310 | 3,355 | -75 | -2.2% | 25,100 |
2024/09/27 | 3,490 | 3,520 | 3,410 | 3,430 | -100 | -2.8% | 30,400 |
2024/09/26 | 3,390 | 3,530 | 3,390 | 3,530 | +175 | +5.2% | 69,800 |
2024/09/25 | 3,290 | 3,375 | 3,230 | 3,355 | +65 | +2% | 30,700 |
2024/09/24 | 3,300 | 3,310 | 3,275 | 3,290 | +10 | +0.3% | 19,100 |
2024/09/20 | 3,260 | 3,310 | 3,250 | 3,280 | +20 | +0.6% | 40,000 |
2024/09/19 | 3,230 | 3,265 | 3,230 | 3,260 | +30 | +0.9% | 23,700 |
2024/09/18 | 3,175 | 3,230 | 3,175 | 3,230 | +10 | +0.3% | 18,500 |
2024/09/17 | 3,220 | 3,225 | 3,175 | 3,220 | +35 | +1.1% | 17,500 |
2024/09/13 | 3,240 | 3,240 | 3,185 | 3,185 | -55 | -1.7% | 25,700 |
2024/09/12 | 3,260 | 3,275 | 3,200 | 3,240 | +20 | +0.6% | 20,900 |
2024/09/11 | 3,210 | 3,250 | 3,195 | 3,220 | -25 | -0.8% | 25,500 |
2024/09/10 | 3,300 | 3,325 | 3,245 | 3,245 | -55 | -1.7% | 11,800 |
2024/09/09 | 3,295 | 3,320 | 3,260 | 3,300 | +10 | +0.3% | 12,500 |
2024/09/06 | 3,330 | 3,330 | 3,290 | 3,290 | -15 | -0.5% | 18,600 |
2024/09/05 | 3,270 | 3,310 | 3,265 | 3,305 | +15 | +0.5% | 19,200 |
2024/09/04 | 3,280 | 3,335 | 3,265 | 3,290 | -45 | -1.3% | 19,600 |
2024/09/03 | 3,285 | 3,375 | 3,285 | 3,335 | +55 | +1.7% | 18,200 |
2024/09/02 | 3,300 | 3,320 | 3,240 | 3,280 | -20 | -0.6% | 13,900 |
2024/08/30 | 3,320 | 3,335 | 3,300 | 3,300 | +15 | +0.5% | 20,900 |
2024/08/29 | 3,320 | 3,340 | 3,280 | 3,285 | -55 | -1.6% | 10,500 |
2024/08/28 | 3,310 | 3,345 | 3,290 | 3,340 | +10 | +0.3% | 8,500 |
2024/08/27 | 3,310 | 3,355 | 3,310 | 3,330 | +15 | +0.5% | 10,600 |
2024/08/26 | 3,320 | 3,320 | 3,250 | 3,315 | +30 | +0.9% | 18,300 |
2024/08/23 | 3,280 | 3,320 | 3,275 | 3,285 | +5 | +0.2% | 10,600 |
2024/08/22 | 3,230 | 3,280 | 3,230 | 3,280 | +50 | +1.5% | 8,200 |
2024/08/21 | 3,255 | 3,280 | 3,220 | 3,230 | -70 | -2.1% | 9,600 |
2024/08/20 | 3,255 | 3,300 | 3,245 | 3,300 | +60 | +1.9% | 11,900 |
2024/08/19 | 3,255 | 3,290 | 3,215 | 3,240 | -50 | -1.5% | 35,100 |
2024/08/16 | 3,290 | 3,295 | 3,235 | 3,290 | +55 | +1.7% | 17,000 |
2024/08/15 | 3,260 | 3,260 | 3,225 | 3,235 | -20 | -0.6% | 16,000 |
2024/08/14 | 3,245 | 3,260 | 3,185 | 3,255 | +10 | +0.3% | 13,100 |
2024/08/13 | 3,125 | 3,285 | 3,125 | 3,245 | +50 | +1.6% | 17,500 |
2024/08/09 | 3,260 | 3,280 | 3,155 | 3,195 | +5 | +0.2% | 49,700 |
2024/08/08 | 3,165 | 3,250 | 3,085 | 3,190 | +5 | +0.2% | 26,800 |
2024/08/07 | 3,075 | 3,250 | 3,060 | 3,185 | +80 | +2.6% | 29,800 |
2024/08/06 | 3,245 | 3,245 | 3,030 | 3,105 | +70 | +2.3% | 50,700 |
2024/08/05 | 3,085 | 3,225 | 2,961 | 3,035 | -180 | -5.6% | 50,900 |
2024/08/02 | 3,310 | 3,335 | 3,135 | 3,215 | -265 | -7.6% | 84,900 |
2024/08/01 | 3,540 | 3,540 | 3,420 | 3,480 | -60 | -1.7% | 29,300 |
2024/07/31 | 3,415 | 3,540 | 3,415 | 3,540 | +80 | +2.3% | 34,300 |
2024/07/30 | 3,515 | 3,525 | 3,455 | 3,460 | -40 | -1.1% | 27,500 |
2024/07/29 | 3,485 | 3,520 | 3,440 | 3,500 | +15 | +0.4% | 33,300 |
2024/07/26 | 3,495 | 3,545 | 3,485 | 3,485 | +25 | +0.7% | 47,000 |
151~
200
件表示中 / 3705件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 297,600円 | +5.1% | -7.0% | 2.69% | 19.54倍 | 0.81倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 297,100円 | +21.7% | +999.9% | 0.00% | 12.45倍 | 4.12倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
ゼリア新薬 | 213,700円 | +3.1% | -6.5% | 2.25% | 9.92倍 | 1.05倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 146,000円 | -2.4% | -52.3% | 3.90% | 17.47倍 | 0.62倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 200,000円 | +4.1% | -3.1% | 2.90% | 17.54倍 | 1.53倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム